Blue Earth Diagnostics Ltd.
Radioactive imaging agent detects prostate cancer recurrence
This article was originally published in Start Up
Executive Summary
Identifying the precise anatomical site of recurring prostate cancer determines how the disease is treated, however, the standard of care – a CT scan or MRI scan – accurately detects recurrent cancer only about 10% of the time. Blue Earth Diagnostics Ltd. believes its radioactive imaging agent, fluciclovine (18F), used in conjunction with a positron emission tomography scanner, could allow for a substantially higher detection rate.